PLoS ONE (Jan 2021)

The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling.

  • Milad J Alasady,
  • Alexander R Terry,
  • Adam D Pierce,
  • Michael C Cavalier,
  • Catherine S Blaha,
  • Kaylin A Adipietro,
  • Paul T Wilder,
  • David J Weber,
  • Nissim Hay

DOI
https://doi.org/10.1371/journal.pone.0256238
Journal volume & issue
Vol. 16, no. 8
p. e0256238

Abstract

Read online

S100B is frequently elevated in malignant melanoma. A regulatory mechanism was uncovered here in which elevated S100B lowers mRNA and secreted protein levels of interleukin-6 (IL6) and inhibits an autocrine loop whereby IL6 activates STAT3 signaling. Our results showed that S100B affects IL6 expression transcriptionally. S100B was shown to form a calcium-dependent protein complex with the p90 ribosomal S6 kinase (RSK), which in turn sequesters RSK into the cytoplasm. Consistently, S100B inhibition was found to restore phosphorylation of a nuclear located RSK substrate, CREB, which is a potent transcription factor for IL6 expression. Thus, elevated S100B reduces IL6-STAT3 signaling via RSK signaling pathway in malignant melanoma. Indeed, the elevated S100B levels in malignant melanoma cell lines correspond to low levels of IL6 and p-STAT3.